Emergency thrombolysis in acute myocardial infarction.

[1]  V. Fuster,et al.  Platelets, vasoconstriction, and nitroglycerin during arterial wall injury. A new antithrombotic role for an old drug. , 1988, Circulation.

[2]  V. Fuster,et al.  Importance of adequate heparin dosage in arterial angioplasty in a porcine model. , 1988, Circulation.

[3]  Dwight E. Peake,et al.  Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .

[4]  J. Anderson,et al.  Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. , 1988, Journal of the American College of Cardiology.

[5]  V. Fuster,et al.  Insights into the pathogenesis of acute ischemic syndromes. , 1988, Circulation.

[6]  V. Fuster,et al.  Thrombolysis in acute myocardial infarction. , 1988, Cardiology clinics.

[7]  B. Waller.  The pathology of acute myocardial infarction: definition, location, pathogenesis, effects of reperfusion, complications, and sequelae. , 1988, Cardiology clinics.

[8]  H. Lambertz,et al.  THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.

[9]  E. B. Carlson,et al.  Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase. , 1988, Circulation.

[10]  E. Topol,et al.  A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. , 1987, The New England journal of medicine.

[11]  M. Christopher.  Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between IV tissue plasminogen activator and IV streptokinaseChesebro JH, Knatterud G, Roberts R, et al Circulation 76:142–154 Jul 1987 , 1987 .

[12]  B. Chaitman,et al.  The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. , 1987, Journal of the American College of Cardiology.

[13]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  LONG-TERM EFFECTS OF INTRAVENOUS THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION: FINAL REPORT OF THE GISSI STUDY , 1987, The Lancet.

[14]  H. White,et al.  Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. , 1987, The New England journal of medicine.

[15]  E. Braunwald,et al.  Update from the Thrombolysis in Myocardial Infarction Trial. , 1987, Journal of the American College of Cardiology.

[16]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[17]  S. Forman,et al.  Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. , 1987, Journal of the American College of Cardiology.

[18]  D. Collen,et al.  Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction. , 1987, The American journal of cardiology.

[19]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[20]  F H Sheehan,et al.  The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. , 1987, Circulation.

[21]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[22]  P. Shah,et al.  Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase. , 1987, The American journal of cardiology.

[23]  V. Fuster,et al.  Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. , 1987, Circulation.

[24]  V. Fuster,et al.  Antithrombotic therapy for acute myocardial infarction: mechanisms and prevention of deep venous, left ventricular, and coronary artery thromboembolism. , 1986, Circulation.

[25]  H. Hod,et al.  Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. , 1986, Circulation.

[26]  R. Kleiger,et al.  Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial. , 1986, The New England journal of medicine.

[27]  A. Jaffe,et al.  Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. , 1986, Journal of the American College of Cardiology.

[28]  V. Fuster,et al.  Influence of Arterial Damage and Wall Shear Rate on Platelet Deposition: Ex Vivo Study in a Swine Model , 1986, Arteriosclerosis.

[29]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico.,et al.  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[30]  M. Gotsman,et al.  Prevention of myocardial damage in acute myocardial ischemia by early treatment with intravenous streptokinase. , 1985, The New England journal of medicine.

[31]  M. Simoons,et al.  IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION A Randomised Trial by the Interuniversity Cardiology Institute in The Netherlands , 1985, The Lancet.

[32]  F. Sheehan,et al.  Time from onset of symptoms to thrombolytic therapy: a major determinant of myocardial salvage in patients with acute transmural infarction. , 1985, Journal of the American College of Cardiology.

[33]  K. Rentrop,et al.  Thrombolytic therapy in patients with acute myocardial infarction. , 1985, Circulation.

[34]  D. Holmes,et al.  Intracoronary thrombus: role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. , 1985, Journal of the American College of Cardiology.

[35]  S. M. Collins,et al.  Rethrombosis after reperfusion with streptokinase: importance of geometry of residual lesions. , 1984, Circulation.

[36]  M. LeWinter,et al.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.

[37]  P. R. Frederick,et al.  A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. , 1983, The New England journal of medicine.

[38]  W. O’Neill,et al.  Intracoronary fibrinolytic therapy in acute myocardial infarction. Report of a prospective randomized trial. , 1983, The New England journal of medicine.

[39]  M. Verstraete,et al.  Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. , 1983, The Journal of clinical investigation.

[40]  W. Weimar,et al.  SPECIFIC LYSIS OF AN ILIOFEMORAL THROMBUS BY ADMINISTRATION OF EXTRINSIC (TISSUE-TYPE) PLASMINOGEN ACTIVATOR , 1981, The Lancet.

[41]  M. Verstraete,et al.  Streptokinase in acute myocardial infarction , 1981 .

[42]  D. Berman,et al.  Intracoronary thrombolysis in evolving myocardial infarction. , 1981, American heart journal.

[43]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[44]  D. Collen.  On the Regulation and Control of Fibrinolysis , 1980, Thrombosis and Haemostasis.

[45]  K. Karsch,et al.  Acute myocardial infarction: Intracoronary application of nitroglycerin and streptokinase , 1979, Clinical cardiology.

[46]  W. Schaper,et al.  Der experimentelle Infarkt , 1979 .

[47]  R. Capone,et al.  Myocardial hemorrhage after coronary reperfusion in pigs. , 1978, The American journal of cardiology.

[48]  Chazov Ei,et al.  Intracoronary administration of fibrinolysin in acute myocardial infarct , 1976 .

[49]  H. Wang,et al.  Experimental coronary arterial occlusion and release. Effects on enzymes, electrocardiograms, myocardial contractility and reactive hyperemia. , 1975, The American journal of cardiology.

[50]  V. Mathur,et al.  Maximal revascularization (reperfusion) in intact conscious dogs after 2 to 5 hours of coronary occlusion. , 1975, The American journal of cardiology.

[51]  G. Grant,et al.  Letter: SI units. , 1974, Lancet.

[52]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[53]  G. T. Smith,et al.  Myocardial viability after transient ischemia in primates. , 1974, The Journal of thoracic and cardiovascular surgery.

[54]  A. Blalock.  Surgical treatment of pulmonary stenosis. , 1947, Lancet.